Oxidative stress and extracellular nucleosomes in critically ill patients with acute kidney failure treated with continuous renal replacement therapies.Effect of two anticoagulation strategies of the extracorporeal purification system in renal function recovery.

Fernando Sánchez0 个研究点开始时间: 2017年2月10日最近更新: 2017年4月3日

试验速览

暂无简介。

•Adult intensive care patients (age = 18 years) admitted to the ICU with ARF requiring treatment with continuous renal replacement technique.
•Patients able to accept being included in the study by signing the Informed Consent (IC). If the patient can not give consent, family consent is requested and, by default, the opinion of the person of trust or designated decision, if present. If there is no family present, trusted person or legal representative designated, the possibility of deferred consent is not contemplated. In this case the patient will not be included in the study.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 22
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 22

•Age under 18 or over 80 years.
•Pregnancy and/or lactation.
•Terminal diseases or life expectancy lower than 48 hours.
•Increased risk of bleeding (defined as platelet count less than 40x109 / L, partial thromboplastin time -TTPA- over 60 seconds, prothrombin time international normalized ratio -PT-INR- greater than 2.0 or recent major bleeding).
•Need of systemic anticoagulation therapy.
•Contraindication for heparin.
•Heparin-induced Thrombocytopenia (HIT).
•Dialysis in the 24 hours prior to inclusion.
•hypercalcemia (> 3 mmol / L).
•Severe Hepatitis (GOT or GPT> 1000 IU / L).
•Cirrhosis.
•Inclusion in another research protocol.

发起方

Fernando Sánchez